Physician experiences in management of COVID‐19‐associated coagulopathy in pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis

• Published in: Journal of Thrombosis and Haemostasis 2021-10, Vol.19 (10), p.2539-2545
• Main Authors: Jevtic, Stefan D., Malinowski, Ann Kinga, Othman, Maha, Abdul Kadir, Rezan A.
• Format: Article
• Language: English
• Subjects: anticoagulant; Anticoagulants; Anticoagulants - adverse effects; Brief Report; coagulopathy; Communication; Coronaviruses; COVID-19; Dosage; Female; Hemostasis; Heparin; Humans; Infections; Lymphopenia; Molecular weight; Physicians; Pregnancy; Risk factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Thrombocytopenia; Thromboembolism; THROMBOSIS; Thrombosis - drug therapy; Women's Health; Womens health
• ISSN: 1538-7933; 1538-7836; 1538-7836
• DOI: 10.1111/jth.15462

Background Coronavirus disease 2019 (COVID‐19) occurs following infection with the potentially fatal, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) virus. Infection can be complicated by coagulopathy, at times featuring thrombocytopenia and thrombosis alongside other coagulation abnormalities, also termed COVID‐19‐associated coagulopathy (CAC). Data concerning CAC in pregnancy are limited. Better understanding of physician experiences is essential to identify current practice patterns and knowledge gaps. Objectives To determine physician experiences and practice patterns regarding CAC in pregnancy. Methods Self‐administered survey using the RedCap online platform; supported by the ISTH Subcommittee on Women's Health Issues in Thrombosis and Hemostasis. Results Seventy‐five respondents fully or partially completed the survey. Of 1546 reported cases, disease severity was specified in 1298. Sixty‐four percent of COVID‐19 infections were mild, whereas 4% were severe. Of all cases, 1% developed CAC, with 65% classified as severe. The most frequent abnormalities included thrombocytopenia, elevated C‐reactive protein, D‐dimer, and lymphopenia. Low molecular weight heparin was the anticoagulant of choice in CAC and was provided by 77% of respondents, with 60% using standard prophylactic dosing. Thrombosis occurred in seven anticoagulated patients who were receiving standard prophylactic (four) or weight‐based (three) dosing. Disease severity and additional thrombosis risk factors dictated anticoagulation duration. Conclusion In the select population reported by our survey, CAC appears to be uncommon in pregnancy. Anticoagulation practices vary and may not reflect current guidelines. Venous thromboembolism was observed in some CAC patients despite prophylactic anticoagulation (including standard and weight‐adjusted dosing). Urgent research is required to determine appropriate anticoagulant dosing and duration in pregnant women with COVID‐19 infection.